When is it appropriate to order a carcinoembryonic antigen (CEA) test and how should the results be interpreted in patients with known CEA‑producing malignancies?

When to Order CEA Testing

CEA should NOT be used for cancer screening, but is indicated for preoperative staging in colorectal cancer patients, postoperative surveillance every 3 months for at least 3 years in stage II-III disease (if the patient is a surgical/systemic therapy candidate), and monitoring metastatic disease every 1-3 months during active treatment. 1

Appropriate Clinical Indications

Colorectal Cancer - Primary Use

Preoperative Staging:

• Order CEA before surgery if results will influence staging or surgical planning
• Elevated preoperative CEA (≥5 ng/mL) correlates with poorer prognosis
• However, CEA alone should NOT determine whether to give adjuvant therapy 1

Postoperative Surveillance (Stage II-III):

• Test every 3 months for at least 3 years after diagnosis 1
• Critical caveat: Only perform if patient is a candidate for surgery or systemic therapy - do not test patients with severe comorbidities who cannot tolerate intervention 2
• Wait until chemotherapy is finished before starting surveillance, as chemotherapy can falsely elevate CEA 1
• 80% of recurrences occur in first 2-2.5 years, so more frequent testing (every 3 months) is justified during this high-risk period 2
• May extend to every 6 months after year 2, then annually 2

Monitoring Metastatic Disease:

• Measure at treatment initiation, then every 1-3 months during active therapy 1
• CEA is the marker of choice for monitoring response to systemic therapy in metastatic colorectal cancer 1

Other CEA-Producing Malignancies

While the guidelines focus on colorectal cancer, CEA can be elevated in:

• Medullary thyroid carcinoma (often markedly elevated and useful for monitoring) 3
• Non-small cell lung cancer (particularly EGFR-mutant tumors show highest levels) 4
• Breast cancer (40-50% show CEA rise as first sign of recurrence) 5
• Pancreatic cancer (though CA 19-9 is preferred) 1

Interpreting CEA Results

Normal vs. Elevated Thresholds

Standard threshold: 5 ng/mL is the traditional cutoff 1

However, recent evidence suggests a more nuanced approach:

• For single test results, consider raising the threshold to 10 ng/mL to reduce false positives 6
• At 5 ng/mL threshold: sensitivity is only 50%, and 4 in 10 patients without recurrence will have at least one false alarm 6

Critical Interpretation Principles

Confirm before acting:

• An elevated CEA warrants retesting for confirmation 1
• Elevated CEA alone does NOT justify starting systemic therapy - requires imaging confirmation 1

Trend analysis is superior to single values:

• Monitoring CEA trends over time is more accurate than single measurements (AUC 0.85 vs 0.74) 6
• Persistently rising values above baseline suggest progressive disease even without radiographic confirmation 1
• After the second CEA test, base investigation decisions on the trend rather than absolute values 6

Timing matters:

• Spurious early rises can occur in first 4-6 weeks of new therapy, especially with oxaliplatin 1
• CEA elevations within 1-2 weeks after chemotherapy should be interpreted with caution 1
• CEA typically rises 3-5 months before clinical detection of recurrence 6, 7

False positives are common:

• Smokers have higher baseline CEA and more false alarms - consider not using CEA monitoring in active smokers 6
• Benign conditions can elevate CEA: chronic cholecystitis, inflammatory bowel disease, liver disease, H. pylori gastritis 3, 8

When Elevated CEA Warrants Further Investigation

Colorectal cancer surveillance:

• Single CEA ≥10 ng/mL (confirmed on repeat) 6
• Positive trend in serial measurements (threshold decreases over time as more measurements accrue) 6
• Lead to CT imaging of chest/abdomen/pelvis, not immediate systemic therapy 1

Metastatic disease monitoring:

• Persistently rising values during treatment indicate progression 1
• Prompt restaging with imaging 1

Common Pitfalls to Avoid

1. Do not screen asymptomatic populations - CEA has very low sensitivity in early disease and causes unnecessary anxiety 7, 8

2. Do not use CEA alone to diagnose cancer - sensitivity is too low without metastases 5

3. Do not assume normal preoperative CEA means surveillance is unnecessary - 50-60% of patients with normal preoperative CEA will show elevation with recurrence 9

4. Do not order surveillance tests in patients who cannot tolerate intervention - this is wasteful and causes harm 2

5. Do not start chemotherapy based on CEA elevation alone - always confirm with imaging 1

6. Do not ignore the clinical context - elevated CEA in absence of appropriate indication leads to diagnostic confusion 8

Optimal Surveillance Algorithm (Colorectal Cancer)

Year 1 (highest risk):

• CEA every 3 months (or monthly for 3 months, then every 2 months per newer data) 1, 6
• Annual CT chest/abdomen (pelvic CT every 6-12 months if rectal primary) 2

Years 2-3:

• CEA every 3-6 months 1, 2
• Annual CT imaging 2

Years 4-5:

• Consider stopping surveillance as conditional survival rates are very high and recurrence curves flatten 2
• If continuing, CEA every 6 months

Action thresholds:

• First two tests: investigate if ≥10 ng/mL 6
• Subsequent tests: investigate based on positive trend (optimal threshold decreases over time) 6